Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 3
2019 4
2020 3
2021 5
2022 22
2023 13
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Omicron BA.1, BA.2 and COVID-19 Booster Vaccination.
Assawakosri S, Kanokudom S, Suntronwong N, Puenpa J, Duangchinda T, Chantima W, Pakchotanon P, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Assawakosri S, et al. Among authors: suntronwong n. J Infect Dis. 2022 Oct 17;226(8):1480-1481. doi: 10.1093/infdis/jiac158. J Infect Dis. 2022. PMID: 35481828 Free PMC article. No abstract available.
Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis.
Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, Moore DP, Nunes M, Rath B, Campbell H, Nair H; RSV Global Epidemiology Network; RESCEU investigators. Li Y, et al. Lancet Glob Health. 2019 Aug;7(8):e1031-e1045. doi: 10.1016/S2214-109X(19)30264-5. Lancet Glob Health. 2019. PMID: 31303294 Free article.
Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination.
Suntronwong N, Kanokudom S, Thatsanathorn T, Thongmee T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2283916. doi: 10.1080/21645515.2023.2283916. Epub 2023 Nov 28. Hum Vaccin Immunother. 2023. PMID: 38014687 Free PMC article.
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Klinfueng S, Sudhinaraset N, Poovorawan Y. Wanlapakorn N, et al. Among authors: suntronwong n. Vaccine. 2022 May 20;40(23):3203-3209. doi: 10.1016/j.vaccine.2022.04.043. Epub 2022 Apr 18. Vaccine. 2022. PMID: 35465981 Free PMC article.
Bacterial microbiota in upper respiratory tract of COVID-19 and influenza patients.
Rattanaburi S, Sawaswong V, Chitcharoen S, Sivapornnukul P, Nimsamer P, Suntronwong N, Puenpa J, Poovorawan Y, Payungporn S. Rattanaburi S, et al. Among authors: suntronwong n. Exp Biol Med (Maywood). 2022 Mar;247(5):409-415. doi: 10.1177/15353702211057473. Epub 2021 Nov 13. Exp Biol Med (Maywood). 2022. PMID: 34775842 Free PMC article.
The impact of COVID-19 and control measures on public health in Thailand, 2020.
Yorsaeng R, Suntronwong N, Thongpan I, Chuchaona W, Lestari FB, Pasittungkul S, Puenpa J, Atsawawaranunt K, Sharma C, Sudhinaraset N, Mungaomklang A, Kitphati R, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: suntronwong n. PeerJ. 2022 Feb 16;10:e12960. doi: 10.7717/peerj.12960. eCollection 2022. PeerJ. 2022. PMID: 35190788 Free PMC article.
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.
Yorsaeng R, Atsawawaranunt K, Suntronwong N, Kanokudom S, Chansaenroj J, Assawakosri S, Nilyanimit P, Aeemjinda R, Khanarat N, Wongsrisang L, Auphimai C, Vichaiwattana P, Klinfueng S, Thongmee T, Srimuan D, Thatsanathorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: suntronwong n. Vaccines (Basel). 2023 Jun 30;11(7):1184. doi: 10.3390/vaccines11071184. Vaccines (Basel). 2023. PMID: 37515001 Free PMC article.
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.
Wanchaijiraboon P, Teeyapun N, Pakvisal N, Sainamthip P, Susiriwatananont T, Zungsontiporn N, Suntronwong N, Vichaiwattana P, Klinsawat W, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Poovorawan Y, Luangdilok S. Wanchaijiraboon P, et al. Among authors: suntronwong n. Vaccines (Basel). 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662. Vaccines (Basel). 2022. PMID: 36298528 Free PMC article.
53 results